Endothelial Cells Lining Sporadic Cerebral Cavernous Malformation Cavernomas Undergo Endothelial-to-Mesenchymal Transition

• Published in: Stroke (1970) 2016-03, Vol.47 (3), p.886-890
• Main Authors: Bravi, Luca, Malinverno, Matteo, Pisati, Federica, Rudini, Noemi, Cuttano, Roberto, Pallini, Roberto, Martini, Maurizio, Larocca, Luigi Maria, Locatelli, Marco, Levi, Vincenzo, Bertani, Giulio Andrea, Dejana, Elisabetta, Lampugnani, Maria Grazia
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Central Nervous System Neoplasms - pathology; Central Nervous System Neoplasms - surgery; Child; Endothelium, Vascular - pathology; Epithelial-Mesenchymal Transition - physiology; Female; Hemangioma, Cavernous, Central Nervous System - pathology; Hemangioma, Cavernous, Central Nervous System - surgery; Humans; Male; Middle Aged; Young Adult
• ISSN: 0039-2499; 1524-4628; 1524-4628
• DOI: 10.1161/STROKEAHA.115.011867

Cerebral cavernous malformation (CCM) is characterized by multiple lumen vascular malformations in the central nervous system that can cause neurological symptoms and brain hemorrhages. About 20% of CCM patients have an inherited form of the disease with ubiquitous loss-of-function mutation in any one of 3 genes CCM1, CCM2, and CCM3. The rest of patients develop sporadic vascular lesions histologically similar to those of the inherited form and likely mediated by a biallelic acquired mutation of CCM genes in the brain vasculature. However, the molecular phenotypic features of endothelial cells in CCM lesions in sporadic patients are still poorly described. This information is crucial for a targeted therapy. We used immunofluorescence microscopy and immunohistochemistry to analyze the expression of endothelial-to-mesenchymal transition markers in the cavernoma of sporadic CCM patients in parallel with human familial cavernoma as a reference control. We report here that endothelial cells, a cell type critically involved in CCM development, undergo endothelial-to-mesenchymal transition in the lesions of sporadic patients. This switch in endothelial phenotype has been described only in genetic CCM patients and in murine models of the disease. In addition, TGF-β/p-Smad- and β-catenin-dependent signaling pathways seem activated in sporadic cavernomas as in familial ones. Our findings support the use of common therapeutic strategies for both sporadic and genetic CCM malformations.